tetano
Editor, Senior Moderator
ERJ Open Res
. 2022 Mar 21;8(1):00577-2021.
doi: 10.1183/23120541.00577-2021. eCollection 2022 Jan.
New domiciliary supplemental oxygen therapy after hospitalisation for COVID-19 in metropolitan Chicago
Malvika Kaul[SUP] 1 2 3 [/SUP], Preeti Gupta[SUP] 1 2 [/SUP], Salil Kalra[SUP] 1 2 [/SUP], Jessica Gardner[SUP] 3 [/SUP], Howard S Gordon[SUP] 2 3 4 [/SUP], Israel Rubinstein[SUP] 1 2 3 [/SUP]
Affiliations
Abstract
Background: A knowledge gap exists in understanding the beneficial use and duration of domiciliary supplemental oxygen (DSO) therapy among survivors of coronavirus disease 2019 (COVID-19) hospitalisations with persistent hypoxaemia upon discharge. The purpose of this single centre study was to begin to address this issue.
Methods: In this retrospective study we report features of US military veterans residing in metropolitan Chicago with no prior DSO therapy who survived COVID-19 hospitalisation, were discharged on DSO and were followed for 6 months.
Results: We found that the majority of the 65 elderly patients (median age, 70 years), predominantly obese Black males, who survived COVID-19 hospitalisations at the Jesse Brown VA Medical Center and were discharged on DSO did not undergo a formal 6-min walk test (6MWT) to re-assess ongoing ambulatory supplemental oxygen requirements (46 patients or 71%). Nonetheless, DSO therapy was discontinued in most patients predominantly within 8 weeks of hospital discharge (34 patients, 52%). In addition, a large proportion of patients, obese Black people in particular, who survived COVID-19 hospitalisations and were treated with DSO for at least 8 weeks thereafter developed post-acute sequelae of COVID-19 infection (PASC) (30 patients, 46%).
Conclusions: Given these findings, we recommend that healthcare providers be appraised about proper monitoring and evaluation, including timely performance of 6MWT, of patients who survived COVID-19 hospitalisations and were treated with DSO for persistent hypoxaemia upon discharge. Whether obese Black males who survived COVID-19 hospitalisations and are treated with DSO thereafter have an elevated risk in developing PASC remains to be determined in larger, prospective studies.
. 2022 Mar 21;8(1):00577-2021.
doi: 10.1183/23120541.00577-2021. eCollection 2022 Jan.
New domiciliary supplemental oxygen therapy after hospitalisation for COVID-19 in metropolitan Chicago
Malvika Kaul[SUP] 1 2 3 [/SUP], Preeti Gupta[SUP] 1 2 [/SUP], Salil Kalra[SUP] 1 2 [/SUP], Jessica Gardner[SUP] 3 [/SUP], Howard S Gordon[SUP] 2 3 4 [/SUP], Israel Rubinstein[SUP] 1 2 3 [/SUP]
Affiliations
- PMID: 35345420
- PMCID: PMC8883040
- DOI: 10.1183/23120541.00577-2021
Abstract
Background: A knowledge gap exists in understanding the beneficial use and duration of domiciliary supplemental oxygen (DSO) therapy among survivors of coronavirus disease 2019 (COVID-19) hospitalisations with persistent hypoxaemia upon discharge. The purpose of this single centre study was to begin to address this issue.
Methods: In this retrospective study we report features of US military veterans residing in metropolitan Chicago with no prior DSO therapy who survived COVID-19 hospitalisation, were discharged on DSO and were followed for 6 months.
Results: We found that the majority of the 65 elderly patients (median age, 70 years), predominantly obese Black males, who survived COVID-19 hospitalisations at the Jesse Brown VA Medical Center and were discharged on DSO did not undergo a formal 6-min walk test (6MWT) to re-assess ongoing ambulatory supplemental oxygen requirements (46 patients or 71%). Nonetheless, DSO therapy was discontinued in most patients predominantly within 8 weeks of hospital discharge (34 patients, 52%). In addition, a large proportion of patients, obese Black people in particular, who survived COVID-19 hospitalisations and were treated with DSO for at least 8 weeks thereafter developed post-acute sequelae of COVID-19 infection (PASC) (30 patients, 46%).
Conclusions: Given these findings, we recommend that healthcare providers be appraised about proper monitoring and evaluation, including timely performance of 6MWT, of patients who survived COVID-19 hospitalisations and were treated with DSO for persistent hypoxaemia upon discharge. Whether obese Black males who survived COVID-19 hospitalisations and are treated with DSO thereafter have an elevated risk in developing PASC remains to be determined in larger, prospective studies.